Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic… (NCT04365049) | Clinical Trial Compass
UnknownNot Applicable
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
China100 participantsStarted 2020-04-01
Plain-language summary
The study is a prospective and observational cohort study. The purpose is to to investigate the safety and efficacy of nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma (PDAC)
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. aged 18-75 years;
✓. histologically or cytologically proven diagnosis of pancreatic adenocarcinoma;
✓. treatment-naive locally advanced pancreatic cancer (locally advanced status was determined by our multidisciplinary team based on the National Comprehensive Cancer Network definitions);
✓. no distant metastasis as defined by CT or MRI of the chest, abdomen and pelvis;
✓. at least 1 measurable lesion based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) 1.1;
✓. an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
✕. with any other malignancy within the 5 years before enrolment;
✕. with active infections (bacterial, viral, or fungal) requiring systematic treatment, with hepatitis B or C infection, or a history of HIV infection, or receiving immunosuppressive therapy;
✕. with peripheral sensory neuropathy at a grade \>1;
✕. with a history of allergy or hypersensitivity to the study drugs;